Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04508179 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects
A Phase 1 study, sponsored by 7 Hills Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT04508179 is a Phase 1 study that has completed, run by 7 Hills Pharma. The registered enrollment target is 60 participants.
The verdict
NCT04508179, a Phase 1 study, has completed, sponsored by 7 Hills Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability and pharmacokinetics of 7HP349, an allosteric integrin activator, in healthy male subjects
Interventions
- DRUG 7HP349 Single Ascending Dose
- DRUG 7HP349 Multiple Ascending Dose
- DRUG Placebo Single Ascending Dose
- DRUG Placebo Multiple Ascending Dose
- DRUG 7HP349 Food Effect
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2021-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04508179
The ClinicalTrials.gov registry entry for NCT04508179 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 7 Hills Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 7HP349 Single Ascending Dose is the first listed.
NCT04508179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04508179 about?
NCT04508179 is a clinical study titled "A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects". This study will evaluate the safety, tolerability and pharmacokinetics of 7HP349, an allosteric integrin activator, in healthy male subjects
What is the current status of trial NCT04508179?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2020-10-28. Estimated completion is 2021-10-25.
What interventions are being tested in trial NCT04508179?
The interventions under investigation include: 7HP349 Single Ascending Dose (DRUG), 7HP349 Multiple Ascending Dose (DRUG), Placebo Single Ascending Dose (DRUG), Placebo Multiple Ascending Dose (DRUG), 7HP349 Food Effect (DRUG).
Who is sponsoring clinical trial NCT04508179?
This trial is sponsored by 7 Hills Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.